|
1
|
Ferrari S, Smeland S, Mercuri M, Bertoni
F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini
G, et al Italian and Scandinavian Sarcoma Groups: Neoadjuvant
chemotherapy with high-dose ifosfamide, high-dose methotrexate,
cisplatin, and doxorubicin for patients with localized osteosarcoma
of the extremity: A joint study by the Italian and Scandinavian
Sarcoma Groups. J Clin Oncol. 23:8845–852. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kager L, Zoubek A, Dominkus M, Lang S,
Bodmer N, Jundt G, Klingebiel T, Jürgens H, Gadner H and Bielack S;
COSS Study Group: Osteosarcoma in very young children: Experience
of the Cooperative Osteosarcoma Study Group. Cancer. 116:5316–324.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Campbell CJ, Cohen J and Enneking WF:
Editorial: New therapies for osteogenic sarcoma. J Bone Joint Surg
Am. 57:143–44. 1975.PubMed/NCBI
|
|
4
|
Kawaguchi S, Wada T, Tsukahara T, Ida K,
Torigoe T, Sato N and Yamashita T: A quest for therapeutic antigens
in bone and soft tissue sarcoma. J Transl Med. 3:312005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kawano M, Nishida H, Nakamoto Y, Tsumura H
and Tsuchiya H: Cryoimmunologic antitumor effects enhanced by
dendritic cells in osteosarcoma. Clin Orthop Relat Res.
468:1373–1383. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kanamaru F, Youngnak P, Hashiguchi M,
Nishioka T, Takahashi T, Sakaguchi S, Ishikawa I and Azuma M:
Costimulation via gluco-corticoid-induced TNF receptor in both
conventional and CD25+ regulatory CD4+ T
cells. J Immunol. 172:7306–7314. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McHugh RS, Whitters MJ, Piccirillo CA,
Young DA, Shevach EM, Collins M and Byrne MC: CD4(+)CD25(+)
immunoregulatory T cells: Gene expression analysis reveals a
functional role for the glucocorticoid-induced TNF receptor.
Immunity. 16:311–323. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kohm AP, Williams JS and Miller SD:
Cutting edge: Ligation of the glucocorticoid-induced TNF receptor
enhances autoreactive CD4+ T cell activation and
experimental autoimmune encephalomyelitis. J Immunol.
172:4686–4690. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tone M, Tone Y, Adams E, Yates SF, Frewin
MR, Cobbold SP and Waldmann H: Mouse glucocorticoid-induced tumor
necrosis factor receptor ligand is costimulatory for T cells. Proc
Natl Acad Sci USA. 100:15059–15064. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shimizu J, Yamazaki S, Takahashi T, Ishida
Y and Sakaguchi S: Stimulation of CD25(+)CD4(+) regulatory T cells
through GITR breaks immunological self-tolerance. Nat Immunol.
3:135–142. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stephens GL, McHugh RS, Whitters MJ, Young
DA, Luxenberg D, Carreno BM, Collins M and Shevach EM: Engagement
of glucocorticoid-induced TNFR family-related receptor on effector
T cells by its ligand mediates resistance to suppression by
CD4+CD25+ T cells. J Immunol. 173:5008–5020.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ko K, Yamazaki S, Nakamura K, Nishioka T,
Hirota K, Yamaguchi T, Shimizu J, Nomura T, Chiba T and Sakaguchi
S: Treatment of advanced tumors with agonistic anti-GITR mAb and
its effects on tumor-infiltrating
Foxp3+CD25+CD4+ regulatory T
cells. J Exp Med. 202:885–891. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ramirez-Montagut T, Chow A,
Hirschhorn-Cymerman D, Terwey TH, Kochman AA, Lu S, Miles RC,
Sakaguchi S, Houghton AN and van den Brink MR:
Glucocorticoid-induced TNF receptor family related gene activation
overcomes tolerance/ignorance to melanoma differentiation antigens
and enhances antitumor immunity. J Immunol. 176:6434–6442. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cohen AD, Diab A, Perales MA, Wolchok JD,
Rizzuto G, Merghoub T, Huggins D, Liu C, Turk MJ, Restifo NP, et
al: Agonist anti-GITR antibody enhances vaccine-induced CD8(+)
T-cell responses and tumor immunity. Cancer Res. 66:4904–4912.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nishikawa H, Kato T, Hirayama M, Orito Y,
Sato E, Harada N, Gnjatic S, Old LJ and Shiku H: Regulatory T
cell-resistant CD8+ T cells induced by
glucocorticoid-induced tumor necrosis factor receptor signaling.
Cancer Res. 68:5948–5954. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Turk MJ, Guevara-Patiño JA, Rizzuto GA,
Engelhorn ME, Sakaguchi S and Houghton AN: Concomitant tumor
immunity to a poorly immunogenic melanoma is prevented by
regulatory T cells. J Exp Med. 200:771–782. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lutz MB and Rössner S: Factors influencing
the generation of murine dendritic cells from bone marrow: The
special role of fetal calf serum. Immunobiology. 212:855–862. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chauvin C, Philippeau JM, Hémont C, Hubert
FX, Wittrant Y, Lamoureux F, Trinité B, Heymann D, Rédini F and
Josien R: Killer dendritic cells link innate and adaptive immunity
against established osteosarcoma in rats. Cancer Res. 68:9433–9440.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kawano M, Itonaga I, Iwasaki T, Tsuchiya H
and Tsumura H: Anti-TGF-β antibody combined with dendritic cells
produce antitumor effects in osteosarcoma. Clin Orthop Relat Res.
470:2288–2294. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Southam CM, Marcove RC, Levin AG,
Buchsbaum HJ and Miké V: Proceedings: Clinical trial of autogenous
tumor vaccine for treatment of osteogenic sarcoma. Proc Natl Cancer
Conf. 7:91–100. 1972.PubMed/NCBI
|
|
21
|
Yu Z, Ma B, Zhou Y, Zhang M, Qiu X and Fan
Q: Activation of antitumor cytotoxic T lymphocytes by fusion of
patient-derived dendritic cells with autologous osteosarcoma. Exp
Oncol. 27:273–278. 2005.
|
|
22
|
Piao J, Kamimura Y, Iwai H, Cao Y, Kikuchi
K, Hashiguchi M, Masunaga T, Jiang H, Tamura K, Sakaguchi S, et al:
Enhancement of T-cell-mediated anti-tumour immunity via the
ectopically expressed glucocorticoid-induced tumour necrosis factor
receptor-related receptor ligand (GITRL) on tumours. Immunology.
127:489–499. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Coe D, Begom S, Addey C, White M, Dyson J
and Chai JG: Depletion of regulatory T cells by anti-GITR mAb as a
novel mechanism for cancer immunotherapy. Cancer Immunol
Immunother. 59:1367–1377. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ko HJ, Kim YJ, Kim YS, Chang WS, Ko SY,
Chang SY, Sakaguchi S and Kang CY: A combination of
chemoimmuno-therapies can efficiently break self-tolerance and
induce antitumor immunity in a tolerogenic murine tumor model.
Cancer Res. 67:7477–7486. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nishida H, Tsuchiya H and Tomita K:
Re-implantation of tumour tissue treated by cryotreatment with
liquid nitrogen induces anti-tumour activity against murine
osteosarcoma. J Bone Joint Surg Br. 90:1249–1255. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kawano M, Itonaga I, Iwasaki T and Tsumura
H: Enhancement of antitumor immunity by combining anti-cytotoxic T
lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed
dendritic cells in murine osteosarcoma. Oncol Rep. 29:1001–1006.
2013.PubMed/NCBI
|
|
27
|
Ronchetti S, Zollo O, Bruscoli S, Agostini
M, Bianchini R, Nocentini G, Ayroldi E and Riccardi C: GITR, a
member of the TNF receptor superfamily, is costimulatory to mouse T
lymphocyte subpopulations. Eur J Immunol. 34:613–622. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Viguier M, Lemaître F, Verola O, Cho MS,
Gorochov G, Dubertret L, Bachelez H, Kourilsky P and Ferradini L:
Foxp3 expressing CD4+CD25(high) regulatory T cells are
overrepresented in human metastatic melanoma lymph nodes and
inhibit the function of infiltrating T cells. J Immunol.
173:1444–1453. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nizar S, Meyer B, Galustian C, Kumar D and
Dalgleish A: T regulatory cells, the evolution of targeted
immunotherapy. Biochim Biophys Acta. 1806:7–17. 2010.PubMed/NCBI
|
|
30
|
Baba J, Watanabe S, Saida Y, Tanaka T,
Miyabayashi T, Koshio J, Ichikawa K, Nozaki K, Koya T, Deguchi K,
et al: Depletion of radio-resistant regulatory T cells enhances
antitumor immunity during recovery from lymphopenia. Blood.
120:2417–2427. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Girardin A, McCall J, Black MA, Edwards F,
Phillips V, Taylor ES, Reeve AE and Kemp RA: Inflammatory and
regulatory T cells contribute to a unique immune microenvironment
in tumor tissue of colorectal cancer patients. Int J Cancer.
132:1842–1850. 2013. View Article : Google Scholar
|
|
32
|
Suvas S, Kim B, Sarangi PP, Tone M,
Waldmann H and Rouse BT: In vivo kinetics of GITR and GITR ligand
expression and their functional significance in regulating viral
immunopathology. J Virol. 79:11935–11942. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Valzasina B, Guiducci C, Dislich H,
Killeen N, Weinberg AD and Colombo MP: Triggering of OX40 (CD134)
on CD4(+)CD25+ T cells blocks their inhibitory activity:
A novel regulatory role for OX40 and its comparison with GITR.
Blood. 105:2845–2851. 2005. View Article : Google Scholar
|
